Lenders and borrowers in US leveraged finance markets have had to recalibrate pricing and issuance volume expectations in 2022 in the face of rising inflation and interest rates....more
Following a year of healthy activity, M&A deals in the pipeline are set to sustain leveraged finance issuance in the pharmaceutical, medical and biotech sector in the months ahead -
Lender appetite for exposure to the...more
2/9/2022
/ Acquisitions ,
Biotechnology ,
Borrowers ,
Capital Markets ,
Coronavirus/COVID-19 ,
Environmental Social & Governance (ESG) ,
Financial Services Industry ,
Global Market ,
Healthcare ,
High Yield Bonds ,
Lenders ,
Leveraged Loans ,
Mergers ,
Pharmaceutical Industry